Sertraline and adjunctive olanzapine reduced the risk for relapse in patients with psychotic depression; however, patients experienced such adverse effects of olanzapine as weight gain.
Primary care diabetes prevention programs that promote physical activity become less effective when patients experience depressive symptoms.
Results from both studies showed that treatment with esketamine plus standard of care was clinically meaningful and statistically significantly superior to placebo plus standard of care.
Patients enrolled in the telehealth intervention HOPE saw clinically significant reductions in depression symptoms but not glycemic control.
Prevalence rates of major depressive disorder in patients with borderline personality disorder are higher than those reported by patients with other personality disorders; however, rates of remissions, recurrences, and new onsets were similar in both groups.
The association between disease activity and emotional processing biases may play a role in the higher rates of depression in patients with inflammatory bowel disease.
Approximately one in five patients with major depressive disorder experienced an episode of high or fluctuating suicidal ideation despite treatment with nortriptyline or escitalopram.
There was no evidence of metabolic syndrome’s effect on the course and severity of depression over six years in older adults with a formal diagnosis of depression.
Recent study data shows that amygdala substructures experience volumetric sensitivity to depression symptoms.
Based on improved symptoms measured by the 6-item Hamilton Depression Rating Scale, SSRIs appear to be as effective in patients with nonsevere depression as in patients with severe depression.
